Association between premature ovarian insufficiency and biological aging
Authors' conclusion
This study showed that participants with POI had a significantly increased risk of biological aging compared with those without POI. Participants with POI who received MHT had a reduced risk of aging compared with those who did not.
Study context
- Population
- Participants aged ≥40 years in the UK Biobank (2006–2010) and NHANES (1999–2018)UK Biobank and NHANES
- Participants
- 229,779 participants
- Exposure
- Premature ovarian insufficiency (POI) vs no POI; Menopausal hormone therapy (MHT) vs no MHT in POI
- Outcome
- Biological aging: Klemera-Doubal biological age acceleration >0
Methodological detailsUK Biobank (2006-2010) and NHANES (1999-2018)
- UK Biobank (2006-2010) and NHANES (1999-2018)
Main finding
As reported in the abstract
Biological aging
POI vs Without POIOdds ratio (95% CI)
UK Biobank
1.50(1.24–1.82)
NHANES
1.20(1.07–1.34)
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| Biological aging in POI: MHT vs no MHTMHTvs No MHTUK Biobank | 0.63 (0.43–0.92) | |
| Biological aging in POI: MHT vs no MHTMHTvs No MHTNHANES | 0.75 (0.61–0.92) | |
| 0.512Odds ratio (log scale) |
| Outcome | Decrease (95% CI) |
|---|---|
| Leukocyte telomere length (UK Biobank)Lower with POI; UK Biobank | 0.0109 (0.0079–0.0109) |
Original publication
Association between premature ovarian insufficiency and biological aging. Eur J Endocrinol. Published 9 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →